This application is in response to NOT-OD-09-058 (NIH announces the Availability of Recovery Act Funds Competitive Revision Applications). Enhancing Roswell Park Cancer Institute (RPCI) Clinical Research Processes: Study Implementation, Participant Accrual and a Complete and Accurate Study Dataset RPCI is committed to focusing clinical research resources on processes that will improve the efficiency and effectiveness of study implementation, participant accrual and study data collection with an emphasis on investigator-initiated studies and Phase I studies. This proposal provides for an additional Clinical Research Services (CRS) staff and an Electronic Medical Record (EMR) Programmer (1.0 FTE). The EMR Programmer is needed to facilitate the EMR team in making needed changes that will improve clinical research processes to enhance accrual, prevent study protocol deviations, and enhance the collection of a complete and accurate dataset. The combination of the new CRS position and the 20% salary support for the CRS Educator who will provide consistent education for the investigators and the clinical research coordinators regarding the new EMR clinical research features will enhance the efficiency, effectiveness and accuracy of the RPCI clinical research processes: study implementation, participant accrual and accurate and complete data collection.

Public Health Relevance

The project described will be relevant to public health because it will facilitate and make more accurate the clinical research process and the study data collection process. This will allow clinical research findings to be published in a timelier manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016056-33S1
Application #
7814470
Study Section
Special Emphasis Panel (ZCA1-RTRB-L (O9))
Program Officer
Ciolino, Henry P
Project Start
2009-09-30
Project End
2011-09-29
Budget Start
2009-09-30
Budget End
2011-09-29
Support Year
33
Fiscal Year
2009
Total Cost
$173,231
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Mohammadpour, Hemn; O'Neil, Rachel; Qiu, Jingxin et al. (2018) Blockade of Host ?2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs. J Immunol 200:2479-2488
Hsu, Alice H; Lum, Michelle A; Shim, Kang-Sup et al. (2018) Crosstalk between PKC? and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. Cell Rep 24:655-669
Sandlesh, Poorva; Juang, Thierry; Safina, Alfiya et al. (2018) Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. PLoS One 13:e0199785
Zhang, Dingxiao; Zhao, Shuhong; Li, Xinyun et al. (2018) Prostate Luminal Progenitor Cells in Development and Cancer. Trends Cancer 4:769-783
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Damayanti, Nur P; Budka, Justin A; Khella, Heba W Z et al. (2018) Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clin Cancer Res 24:5977-5989
Mayor, Paul; Starbuck, Kristen; Zsiros, Emese (2018) Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol 150:361-369

Showing the most recent 10 out of 1555 publications